RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the specific objectives and expected outcomes for 'Efficient and Durable Pressurised Anion Exchange Membrane Electrolyser with Novel Triple-Boundary and Stack Designs' in the context of a Horizon Europe call.

assistant: **Objectives**

The Anion Exchange Membrane Electrolyser (AEMEL) demonstrates potential advantages compared with the more established Alkaline Electrolyser and Proton Exchange Membrane Electrolyser in easing the cell design, and lowering capital and operating expenditures. Nevertheless, AEMEL faces challenges due to its poor durability and low efficiency, which demands further research and innovation in Membrane-Electrode-Assembly (MEA) optimisation and cell design. Furthermore, coupling the AEMEL with industry requires another technological challenge in producing direct pressurised hydrogen to the end user. Taking the aforementioned challenges into consideration, ENDURION’s main objective is to develop an efficient, durable, low-cost pressurised AEMEL through the synergistic approach of MEA materials development and novel cell design employing exclusively earth-abundant materials and up-scalable processing. Learning from the previous progress of main EU projects on AEMEL, ENDURION addresses the AEMEL challenges through integrating recent advances in materials science, modern characterisations and processing tools, data-driven optimisation through machine learning, internal and external AEMEL components designed for electrochemical compression. Systematic works on novel materials development of sustainable porous transport layer, CRM-free catalysts, ionic liquid co-catalysts and environmentally benign bioresource membrane, along with novel up-scalable AEMEL cell and stack design will be the main tasks. ENDURION is expected to demonstrate an innovative pressurised AEMEL with a 30 % improved efficiency and 30 % more durable, at H2 production cost reaches EUR 450 /kg H2  It is also projected that ENDURION’s outcomes in the long run will contribute to an increased market share of AEMEL for
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Fourth Framework proposal on 'Health Telematics Project Reports'.

assistant: **Innovation**

HEALTHWATCH will survey telematics projects with clinical and health care applications, for a more effective allocation of EU resources in the field. A database of current projects in the EU, Norway and Switzerland will yield an appraisal of funding trends, project impact on quality care, and the adoption of innovative technologies. Industry and the health care sector will thus gain a better grasp of Member State developments, which is currently hindered by their very varied funding mechanisms. Project design has been sensitive to survey user needs, and a comparative summary for North America is also intended.Identification, description and evaluation of significant Health Care telematics projects related to clinical and patient care applications in EU countries with summarised US comparison.A database of current healthcare telematics projects in the EU, Norway and Switzerland will be compiled, and through a formal evaluation of these projects trends in the funding of these projects, the impact of the projects on improving the quality of healthcare and the adoption of innovative technologies will be assessed. A comparative summary will be produced for North America. The study will be undertaken by a consortium of four companies, which have their headquarters in the UK, France, Italy and Spain.In designing the project care has been taken to meet the needs of a range of users of the results of the survey.The database will substantially improve the capability of the health community and the industry to assess the status and trends in Member States, where a multiplicity of funding mechanisms hinders a clear understanding of achievements and obstacles to progress. The database will identify current and planned projects throughout the EU, enabling Community resources to be al
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'Environmental research institute transfer of atmospheric science knowledge' (ERITASK).

assistant: **Concept**

A full understanding of the impact of atmospheric pollution on human health and the ecology of the Earth System requires a scientific approach, which links laboratory experiments to field measurements to predictive models. Epidemiological studies especiall y have emphasised the role played by particulate matter (PM) on health. However despite several studies that have strengthened their causal association, the toxicity mechanism is currently unclear because few symbiotic studies have been performed, which re late PM to source, chemical composition and atmospheric ageing. Therefore ERITASK will be established at University College Cork (UCC) to bring individuals with appropriate complementary research backgrounds together to achieve this aim. Whilst facilities for the analysis of chemical compounds are available and the toxic effects of chemicals deposited in soils are studied, no expertise to make atmospheric field measurements or associated source apportionment modelling exists. Moreover no experience to perfo rm in vitro studies assessing the toxic effects of fine particles on human pulmonary epithelial cell and macrophage cultures is available. Therefore four expert postdoctoral researchers with skills not available at UCC are assessed to be necessary in order to ensure success for this ToK activity. The expertises required are divided as follows: (i) Field measurement of particulate matter; (ii) 'Total' chemical analysis of the particulate matter; (iii) Source apportionment modelling; (iv) Biochemical toxicolo gy of air particulate components. A successful outcome to the spectrum of research objectives given for ERITASK will require the researchers to build on their own skill-bases, to develop expertise in new techniques (in order to suitably communicate on the wide
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the 'Expected Impact' section for the project 'Assessment of the accuracy of different phylogenetic methods for HIV-1 contact tracing and HIV-1 molecular epidemiology in Greece' (2002-2006), addressing dissemination and exploitation.

assistant: **Impact**

HIV-1 is one of the most genetically variable human pathogens. Given this extremely high evolutionary rate of the virus, we can trace the recent spread of the HIV-1 epidemic using molecular data. Phylogenetic analyses have been used in monitoring the molec ular epidemiology of HIV-1 at a global scale, within single countries and risk groups, or for the investigation of the HIV-1 transmission in several cases of uncertain histories. The accuracy of different phylogenetic methods, to truly reconstruct HIV-1 ep idemiological relationships, has been previously investigated by analyzing DNA sequences from patients, for which the transmission events and dates were accurately known. (HIV-1 Swedish transmission chain) Although analyses of DNA sequences isolated from p atients infected from a single source (transmission chains) provide valuable information about the evolution of the virus after sequential transmissions, as well as about the levels of concordance between the evolutionary tree and the transmission tree; th ey don¿t provide evidence about the ability of different phylogenetic methods to truly reconstruct potential clusters of epidemiologically closely linked patients within a population. It is our objective to address the latter question, by analyzing HIV-1 s equences isolated from individuals, for which the close epidemiological link has been independently documented, including also sequences from diverse origin; thus searching for the optimal methodology for HIV-1 contact tracing. Moreover, we will perform a molecular epidemiology study of HIV-1 infection in Greece; investigating how the epidemic spreads among and within different transmission risk groups, and inferring the intermixing (migration) rates of viral infection between the Greek residents and immigr an
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the 'Expected Impact' section for the project 'BIOabsorbable Metallic ENDovascular Medical Devices (BIOMEND) Doctoral Network' (BIOMEND), addressing dissemination and exploitation.

assistant: **Impact**

BIOMEND is an Industrial Doctorate Network (DN) programme that will provide world-class interdisciplinary training to 15 high-achieving doctoral candidates (DCs) in the area of BIOabsorbable Metallic ENdovascular Medical Devices (BIOMEND). The consortium spans seven European countries and comprises of leading academic, clinical and industry experts to promote international, interdisciplinary and inter-sectoral aspects of DC skill development. The research objective of BIOMEND is to develop next-generation bioabsorbable metals for endovascular medical devices for both cardiovascular and peripheral applications. BIOMEND will achieve this through the development of ultra-fine grain Magnesium and Zinc alloys that exhibit high strength, excellent creep performance and high ductility, with enhanced corrosion properties delivered by multi-layer coating technologies. These novel Magnesium and Zinc metal alloys will be leveraged to develop, design and fabricate a range of innovate bioabsorbable metallic endovascular medical devices across both cardiovascular and peripheral applications. Pre-clinical evaluation will be conducted to demonstrate enhanced functional performance of bioabsorbable metal endovascular medical devices in both acute and long-term animal models. These medical devices have the potential to be technology disruptors in endovascular medicine and all DCs will be involved in establishing a clear roadmap for their commercialisation through exploitation activities. Apart from these technological breakthroughs, BIOMEND programme will make significant scientific impact by developing novel ultra-fine grain Mg & Zn alloys and establishing new structure-property-processing relationships describing their performance.  The comprehensive skillset delivered by the programme
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the specific objectives and expected outcomes for 'Mechanism-based influenza neuraminidase inhibitors as antivirals to combat flu infections' in the context of a Horizon Europe call.

assistant: **Objectives**

Influenza neuraminidases are the primary target for anti-influenza small molecule drugs and are retaining glycosidases that form a transient covalent intermediate during substrate hydrolysis. Oseltamivir (Tamiflu) and Zanamivir (Relenza), the two small-molecule anti-influenza drugs used primarily for early onset treatment of flu infections, inhibit influenza neuraminidases competitively (and thus reversibly). The AziFlu ERC PoC proposal is rooted in our finding that N-acyl Oseltamivir aziridines, or Aziflus, inhibit influenza neuraminidase covalently. They block viral outgrowth in an infected cell model. Our compounds are at least as potent as Oseltamivir. Rather than temporarily disabling influenza neuraminidases, our technology acts in an irreversible, permanent, manner. Our drug candidates are selective for influenza neuraminidases over human neuraminidases, and we propose they may be more effective than existing drugs and may also find use as prophylactics and to treat later disease stages. The AziFlu program will develop our mechanism-based influenza neuraminidase inhibition technology and take the first steps to create a start-up company for bringing the technology to market. To strengthen our scientific case (experimental development, A), we will (A-I) optimise our leads by the synthesis and biochemical evaluation of comprehensive sets of focused analogues; (A-II) design a synthetic route to prepare gram-scale quantities of selected leads; and (A-III) develop assays for in vitro and in vivo target inhibition efficacy, target engagement, and viral outgrowth studies. To prepare for the establishment of a spin-out biotech company (business development, B) to take our leads towards the clinic we will (B-IV) strengthen our intellectual property (IP) position; (B-V) an
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Polar Ocean Mitigation Potential' (POMP).

assistant: **Innovation**

POMP will advance the scientific understanding of how climate change impacts biodiversity and carbon sequestration potential in emerging and rapidly changing polar marine ecosystems, and, through these impacts, the project will evaluate how resilience and adaptation potential in the polar regions are being altered. The aim is to provide new quantitative knowledge of the mitigation potential of blue carbon in emerging coastal and oceanic habitats and to assess the scope for their inclusion in carbon accounting at national and international levels. Our approach is to study each step in the biological carbon flow from CO2-capture by primary producers, through transformations and intermediate storage, to long-term sequestration. We will do this by combining analyses of new and existing data at several Arctic and Antarctic Learning Sites and use this to develop and validate new ecosystem models and remote sensing algorithms. These will then be used to provide large-scale assessments of changes in blue carbon habitat distributions and their CO2 capture and sequestration potential, both now and in the future. The new knowledge generated will be presented to the scientific community and to decision makers and managers as policy briefs to guide the designation of marine protected areas that recognize both diversity and blue carbon potential. The POMP consortium is highly qualified to meet this task with world-leading experts on blue carbon and climate change impacts in the polar regions, and partners that bring together scientific expertise, extensive unpublished data, polar infrastructure, and unique sampling opportunities as well as experience and resources from several national and EU projects directly related to this call. Participation of three Canadian partners eligible fo
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Ai-aided deCision tool for seamless mUltiModal nEtwork and traffic managemeNt' under Horizon Europe.

assistant: **Concept**

Ai-aided deCision tool for seamless mUltiModal nEtwork and traffic managemeNt (ACUMEN) proposes a generic, privacy-preserving, data-driven modular digital paradigm for advanced network management, which aims at enabling efficient and reliable door-to-door journeys for people and goods, increased safety and resilience at the network level, and to make a critical contribution to achieving the transport goals set forth in the green deal. The main concept developed in ACUMEN is a modular, multi-layered Digital Twin (DT), a high-fidelity representation of integrated and interacting real complex systems, ultimately forming a digitised version of seamless and sustainable, connected urban mobility. This is complemented by plug-in modules, or digital tools, which represent the outcomes of the models (physics-based or data-driven based), data (including that generated via AI/ML approaches using said models), and simulation tools at the disposal of a city/road authority/mobility service provider. AI-powered digital tools supporting mobility management and decision-making, exploiting the modular DT architecture, will be developed by leading academic and research partners, in close cooperation with global industry partners and stakeholders. The DT platform will be demonstrated and validated through a set of comprehensive and carefully selected use cases, co-created with stakeholders, involving different scales and urban forms, to challenge the capabilities of ACUMEN with a diverse range of transport management problems and applications. The ACUMEN consortium (6 Universities - one is the Coordinator, 6 Industrial partners, 2 RTOs , 3 stakeholders) has been formed to address a combination of technical and implementation challenges to develop and successfully launch ACUMEN as a solutio
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe how 'Zebrafish avatar as a real-time in vivo platform for personalized cancer therapeutics' will create measurable scientific, societal and economic impact aligned with Horizon 2020.

assistant: **Impact**

The Zebrafish Lab is a biotechnological company leader in the development and commercialization of novel, tailor-made solutions based on in vivo zebrafish assays. Thanks to the extensive knowledge acquired by the R&D projects performed in the field by our team for many years and a close collaboration with Hospitals and Cancer Research Institutions, we have identified a remarkable opportunity in the ZEBRAONCOFISH project that will mean a 5-year after tax-R.O.I of 425% according to our estimations. The ultimate goal of the project presented as ZEBRAONCOFISH is to complete the technical roadmap required to bring to the healthcare market a novel real time in vivo platform for personalized cancer treatment based on the use of zebrafish “avatars” as personalized, living test tubes.  Cancer is a leading cause of morbidity and mortality with approx. 35 million people affected by this disease and more than 8 million deaths per year. A major difficulty found in effective cancer treatment is the complexity of the biological mechanism underlying cancer onset and disease progression. This is because the genetic makeup and metabolic profile of each individual patient influence the effect of anticancer drugs. As such, different people respond differently to the same therapy.The solution we propose in the ZEBRAONCOFISH project is the use of zebrafish avatars as an in vivo platform to guide therapeutic decisions in actionable cancer patient-directed interventions. These avatars will be created by xenotransplantation (interspecies transplant) of human cancer cell lines/ tumor samples in zebrafish. The chance to carry out a dynamic display of the cancerous process in vivo will offer the unique opportunity to understand the subjacent cancer biology and design tailor-made treatments for eac
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Identification of dna markers for pig meat quality' demonstrating excellence, impact and implementation quality for a Fifth Framework call.

assistant: **Abstract**

Pork meat quality is an economically important and complex trait for which determinants remain mostly unknown. Since meat quality measurements cannot be taken on a live animal it is an important trait where marker-assisted-selection could be applied. Recent studies have shown that a significant component of meat quality variation is genetic. However, only two major genes, which impact on pork meat quality, have been discovered to date, the 'Halothane' and 'RN' genes. Their discovery has led to the creation of DNA markers to select slaughter pigs with improved meat quality. In 2001, the EC funded the 'Quality Pork Genes' project, developed by PIC in association with several European institutions, aiming at ultimately to identify genes involved in meat quality traits. As part of this project, meat quality measurements and RNA, protein and also DNA samples will be collected on animals from divergent breeds with different meat quality characteristics. Association studies between these meat quality traits and gene expression differences between the divergent breeds will be performed in order to identify genes involved in meat quality variation. Using these resources, we plan to identify a large number of single nucleotide polymorphisms (SNPs). In this new project, SNPs present in ~400 genes expressed in pig muscle will be identified. The allele frequency of 100 of these SNPs will be then determined in breeds selected for the 'Quality Pork Genes' project. In the last phase, association studies between these SNPs and meat quality traits will be performed. New markers associated with variation in pig meat quality will be identified. These markers will be used to improve the quality of pork and pork products in marker-assisted-selection programs.